Vor Biopharma Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
VOR$19.98+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $81,949 | $31,360 |
| Marketable securities | 9,977 | 105,815 |
| Prepaid expenses | 4,201 | 3,153 |
| Other current assets | 380 | 475 |
| Total current assets | 96,507 | 140,803 |
| Restricted cash equivalents | 2,413 | 2,413 |
| Property and equipment, net | 6,581 | 10,050 |
| Operating lease right-of-use assets | 35,007 | 40,048 |
| Other assets | 2,383 | 4,812 |
| Total assets | $142,891 | $198,126 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,505 | $815 |
| Accrued liabilities | 12,892 | 10,877 |
| Operating lease liabilities | 4,215 | 3,830 |
| Other current liabilities | — | 50 |
| Total current liabilities | 18,612 | 15,572 |
| Long-term liabilities: | ||
| Operating lease liabilities—non-current | 27,615 | 31,830 |
| Total liabilities | 46,227 | 47,402 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 124,776,152 and 67,901,610 shares issued and 124,776,152 and 67,891,311 shares outstanding as of December 31, 2024 and December 31, 2023, respectively | 13 | 7 |
| Additional paid-in capital | 553,623 | 490,874 |
| Accumulated other comprehensive income (loss) | 22 | (77) |
| Accumulated deficit | (456,994) | (340,080) |
| Total stockholders’ equity | 96,664 | 150,724 |
| Total liabilities and stockholders’ equity | $142,891 | $198,126 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.